| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Licensing, royalties, and other | $392.9M | $42.98M | $29.06M | $44.98M | $228.52M | $57M | $107.94M | $97.31M |
| Product sales | $22.59M | $41.53M | $59.25M | $621.68M | $10.72M | $13.44M | $39.2M | $42.2M |
| Supply sales | — | — | — | $13.65M | $12.82M | $13.77M | $19.61M | $32.64M |
| Cost reimbursements | — | — | — | $11.27M | $6.48M | $45.83M | $28.05M | $27.72M |
| Upfront fee amortization | — | — | — | $19.91M | $12.27M | -$1.08M | $12.82M | $12.11M |
| Nuvaxovid sales | — | — | — | $608.03M | -$2.09M | -$332K | $19.58M | $9.56M |
| Milestones amortization | — | — | — | $9.14M | $5.67M | -$645K | $5.87M | $5.55M |
| Royalties | $0 | $4.56M | -$4.56M | $0 | $5M | $4.2M | $7.8M | $3.52M |
| Support Services | $0 | $354K | $583K | $0 | $300K | $272K | $250K | $100K |
| Total | $415.48M | $84.51M | $88.31M | $666.66M | $239.24M | $70.45M | $147.14M | $139.51M |